Literature DB >> 11236335

[Depressive disorders in neurologic rehabilitation: therapy with paroxetine].

A Erfurth1, M Loew, G Wendler, A Floreanu.   

Abstract

OBJECTIVE: Depression is a common problem in neurological rehabilitation. Although three double-blind studies have shown the efficacy of trazodone, citalopram and nortriptyline, antidepressant drug therapy of poststroke depression is not yet considered a state-of-the-art strategy. In a hospital for neurological rehabilitation we have performed an open study on the effects of the SSRI, paroxetine, in depressive disorders caused by neurological diseases.
METHOD: 111 consecutive admissions were screened for depression and 9 patients were admitted to the study having a HDRS score > or = 14.
RESULTS: 10-40 mg of paroxetine were well tolerated and led to a > or = 50% reduction of the HDRS score in 8/9 patients. A patient with pathological crying, but without depression, was also successfully treated with 20 mg of paroxetine.
CONCLUSIONS: We conclude that the SSRI, paroxetine, is an effective and well-tolerated therapy of depressive disorders caused by various neurological diseases, including also other diagnoses than stroke.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11236335     DOI: 10.1055/s-2001-10499

Source DB:  PubMed          Journal:  Psychiatr Prax        ISSN: 0303-4259


  2 in total

Review 1.  Post-stroke depression: an update.

Authors:  D W Gawronski; M J Reding
Journal:  Curr Atheroscler Rep       Date:  2001-07       Impact factor: 5.113

Review 2.  Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery.

Authors:  Gillian E Mead; Cheng-Fang Hsieh; Rebecca Lee; Mansur A Kutlubaev; Anne Claxton; Graeme J Hankey; Maree L Hackett
Journal:  Cochrane Database Syst Rev       Date:  2012-11-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.